Compare BENF & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BENF | RPID |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 34.7M |
| IPO Year | 2023 | 2021 |
| Metric | BENF | RPID |
|---|---|---|
| Price | $0.71 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 363.1K | 145.1K |
| Earning Date | 11-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | N/A | $16.95 |
| Revenue Next Year | N/A | $17.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $0.50 | $0.65 |
| 52 Week High | $25.13 | $4.94 |
| Indicator | BENF | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 18.07 |
| Support Level | $0.50 | N/A |
| Resistance Level | $3.87 | $2.18 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 12.16 | 12.93 |
Beneficient is a technology-enabled financial services holding company providing liquidity solutions and trust products and services to participants in the alternative assets industry through an online platform, AltAccess. Its services are focused on alternative asset investors, institutional investors, family offices, and fund managers. The company provides liquidity solutions for alternative asset investments through financing and trust structures. The company has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts. The majority of revenue is derived from the Ben Liquidity segment in the form of interest income.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.